Usana Health Sciences Inc USNA
We take great care to ensure that the data presented and summarized in this overview for USANA HEALTH SCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding USNA
View all-
Black Rock Inc. New York, NY1.77MShares$55.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.37MShares$43.3 Million0.0% of portfolio
-
Richard Pzena Pzena Investment Management LLC1.1MShares$34.5 Million0.11% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.09MShares$34.2 Million0.05% of portfolio
-
Dimensional Fund Advisors LP Austin, TX852KShares$26.9 Million0.01% of portfolio
-
State Street Corp Boston, MA451KShares$14.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA320KShares$10.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY299KShares$9.42 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO255KShares$8.05 Million0.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ189KShares$5.94 Million0.02% of portfolio
Latest Institutional Activity in USNA
Top Purchases
Top Sells
About USNA
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Insider Transactions at USNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 09
2025
|
John Turman Fleming Director |
SELL
Open market or private sale
|
Direct |
500
-10.64%
|
$14,500
$29.66 P/Share
|
|
May 27
2025
|
Walter Noot CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
6,291
-100.0%
|
$188,730
$30.29 P/Share
|
|
May 09
2025
|
G Doug Iiekking CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,548
-100.0%
|
$131,892
$29.61 P/Share
|
|
May 05
2025
|
Gilbert A Fuller Director |
SELL
Open market or private sale
|
Direct |
674
-100.0%
|
$19,546
$29.82 P/Share
|
|
May 02
2025
|
Frederic J Winssinger Director |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+10.3%
|
-
|
|
May 02
2025
|
Timothy E Wood Director |
SELL
Payment of exercise price or tax liability
|
Direct |
169
-2.22%
|
$4,901
$29.44 P/Share
|
|
May 02
2025
|
Timothy E Wood Director |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+8.14%
|
-
|
|
May 02
2025
|
Peggie Pelosi Director |
SELL
Payment of exercise price or tax liability
|
Direct |
386
-9.49%
|
$11,194
$29.44 P/Share
|
|
May 02
2025
|
Peggie Pelosi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+14.21%
|
-
|
|
May 02
2025
|
J Scott Nixon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+10.77%
|
-
|
|
May 02
2025
|
Myron W Wentz > 10% Shareholder |
SELL
Bona fide gift
|
Indirect |
188,000
-2.43%
|
-
|
|
May 02
2025
|
John Turman Fleming Director |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+12.54%
|
-
|
|
May 02
2025
|
Gilbert A Fuller Director |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+50.0%
|
-
|
|
May 02
2025
|
Xia Ding Director |
SELL
Payment of exercise price or tax liability
|
Direct |
169
-3.59%
|
$4,901
$29.44 P/Share
|
|
May 02
2025
|
Xia Ding Director |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+12.51%
|
-
|
|
Mar 12
2025
|
Joshua Foukas CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,732
-100.0%
|
$183,424
$32.54 P/Share
|
|
Mar 12
2025
|
Brent Neidig CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,743
-100.0%
|
$151,776
$32.34 P/Share
|
|
Mar 11
2025
|
John Turman Fleming Director |
SELL
Open market or private sale
|
Direct |
500
-11.05%
|
$16,500
$33.3 P/Share
|
|
Mar 10
2025
|
David Mulham Mulham CHIEF SALES OFFICER |
SELL
Open market or private sale
|
Direct |
3,234
-20.2%
|
$103,488
$32.98 P/Share
|
|
Mar 06
2025
|
Gilbert A Fuller Director |
SELL
Open market or private sale
|
Direct |
674
-100.0%
|
$20,894
$31.44 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 132K shares |
|---|
| Payment of exercise price or tax liability | 49.2K shares |
|---|---|
| Open market or private sale | 41.3K shares |
| Bona fide gift | 311K shares |